Though GSK has put considerable effort into developing pharmacological treatments for gynecological cancers—including Zejula, ...

led by PARP inhibitor Zejula (niraparib) for ovarian cancer. GSK has now revised its sales growth forecast for 2024 upwards to 7%-9% – up from 5%-7% – and now expects earnings per share growth ...

There's more to come in endometrial cancer as well, with RUBY Part 2 looking at the combination of Jemperli, chemo, and GSK's PARP inhibitor Zejula (niraparib), with results showing improved PFS ...

GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), following a string of exits by companies including Pfizer, UCB, WuXi AppTec and ...

Legalcategory GSK agrees to settle about 80,000 Zantac lawsuits for up to $2.2 bln October 9, 2024 Healthcare & Pharmaceuticalscategory GSK, Pfizer RSV vaccine sales fall in US as millions fewer ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

WASHINGTON — Pharmaceutical industry giant GSK plans to depart the biotechnology industry’s largest trade group, the Biotechnology Innovation Organization.

Teva Pharmaceutical Industries Ltd. ADR-1.50% $19.72B ...

GlaxoSmithKline Pharmaceuticals Ltd. key Products/Revenue Segments include Pharmaceuticals, Service Income and Other Operating Revenue for the year ending 31-Mar-2024.For the quarter ended 30-09-2024, ...

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

As of November 08, 2024, GSK plc had a $73.1 billion market capitalization, putting it in the 96th percentile of companies in the Pharmaceuticals industry. Currently, GSK plc’s price-earnings ratio is ...